Tag: Securities and Exchange Commission

BEIJING, June 24, 2026 (GLOBE NEWSWIRE) -- Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (NASDAQ: AZI), one of the leading and fast-growing lifecycle automotive service providers in China, today announced that it entered into a definitive Securities Purchase Agreement (the “Agreement”) with an institutional investor (the “Buyer”) on June 22, 2026, pursuant to which the Company issued to the Buyer an advance promissory note (the “Initial Note”). The closing of the transaction contemplated by the Agreement occurred on June 23, 2026 (the “Closing Date”). The transaction will result in gross proceeds to the Company of up to $5.25 million. Proceeds from the transaction will enhance Autozi’s financial flexibility to support its strategic growth initiatives and expand operational capacity.

Fiscal 2026 Net Income Expected Between $15 Million and $18 Million
Adjusted EBITDA Expected between $75 Million and $77 Million, an increase of 26% to 30%
First Day Program Revenues Estimated to Increase 27% to 28%
Board of Directors Declares Quarterly Dividend of $0.08 per Common Share

366 MWh industrial storage deployment integrates Turbo Energy’s AI optimization platform with HiTHIUM’s advanced battery systems, creating one of Europe’s most advanced software-defined energy infrastructures for industry

Fuel deliveries to approximately 20 generators are expected to continue through mid-July

The Company continues development of two Tokyo projects in the luxury residential and hospitality segments

NORTH PALM BEACH, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”), an AI-enabled platform dedicated to generating returns across high-conviction operating companies and assets, today announced that its Board of Directors has approved a consolidation of the Company's issued and outstanding common stock on a 60-to-1 basis (the “Share Consolidation”), to be effective July 6, 2026 (the “Effective Date”).

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the pricing of an underwritten offering of 10,309,280 common shares in the capital of the Company (the “Common Shares”) at an offering price of US$4.85 per Common Share, for aggregate gross proceeds of US$50 million (the “Offering”).